CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer ...

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory ...

With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...

One of this year’s MPN Heroes® talked about the importance of a supportive care team, especially as every patient with MPN ...

This Christmas, my wish for all of you is that you read this and feel seen, that someone out there knows how very hard this ...

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated ...

In February 2024, the FDA approved Onivyde (irinotecan liposome) with oxaliplatin, fluorouracil and leucovorin for the ...

Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...

Watching "Scrooge" every Christmas made me reflect on my own journey, where my past struggles with illness taught me valuable ...